Simple and efficient method for producing high radionuclidic purity 111In using enriched 112Cd target

Gao, Jing; Liao, Zhonghui; Liu, Weihao; Hu, Yingjiang; Ma, Hongxia; Xia, Lingting; Li, Feize; Lan, Tu; Yang, Yuanyou; Yang, Jijun; Liao, Jiali; Liu, Ning

doi:10.1016/j.apradiso.2021.109828

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In reaction on a CS-30 cyclotron at Institute of Nuclear Science and Technology, Sichuan University. [29] After separated by CL-P204 cation exchange resin, 111 InCl 3 with a high radionuclidic purity of 99.9 % was obtained with a yield of ~220 MBq/(μA•h). All other chemicals were commercially purchased and used without any further purification.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Anticancer Ability of Nano Fluorescent ¹¹¹In‐MIL‐68/PEG‐FA on Hela Cells

Liang

Liao

et al. 2022

Chemistry A European J

Self Cite

View full text Add to dashboard Cite

In past decades, nanoscale metal‐organic frameworks (NMOFs) have drawn more and more attention in multimodal imaging and targeting therapy of various malignant cancers. Here, we proposed to dope 111In into fluorescent In‐based NMOFs (In‐MIL‐68‐NH2), with an attempt to prepare a new nanomedicine with great anticancer potential. As a proof of concept, the obtained NMOF (In‐MIL‐68/PEG‐FA) with targeting motifs is able to act as a fluorescent probe to achieve Hela cell imaging. Moreover, the Auger electron emitter 111In built in corresponding radioactive NMOF (111In‐MIL‐68/PEG‐FA) can bring clear damage to cancer cells, leading to a high cell killing rate of 59.3 % within 48 h. In addition, the cell cycle presented a significant dose‐dependent G2/M inhibiting mode, which indicates that 111In‐MIL‐68/PEG‐FA has the ability to facilitate the cancer cells to enter apoptotic program. This work demonstrated the potential of 111In‐labelled NMOFs in specific killings of cancer cells, providing a new approach to develop nanomedicines with theranostic function.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Materials and characterizations : 111 In was produced by 112 Cd (p, 2n) 111 In reaction on a CS‐30 cyclotron at Institute of Nuclear Science and Technology, Sichuan University [29] . After separated by CL‐P204 cation exchange resin, 111 InCl 3 with a high radionuclidic purity of 99.9 % was obtained with a yield of ∼220 MBq/(μA⋅h).…”

Section: Methodsmentioning

confidence: 99%

In Vitro Anticancer Ability of Nano Fluorescent ¹¹¹In‐MIL‐68/PEG‐FA on Hela Cells

Liang

Liao

et al. 2022

Chemistry A European J

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most common production route of 111 In in a high yield (222 ± 5 MBq/µA.h) is proton irradiation (21 MeV) of enriched 112 Cd target via a 112 Cd (p,2n) 111 In nuclear reaction using a cyclotron [216]. [223] (Table 15).…”

Section: Production and Availabilitymentioning

confidence: 99%

“…Several research studies are ongoing to investigate its dosimetry approach [322][323][324]. 224 Ra is a pure α-emitter that decays via a series of six daughter nuclides ( 220 Rn, 216 Po, 212 Pb, 212 Bi, 212 Po, 208 Tl) and emit overall four alpha particles and two beta particles before stabilizing to 208 Pb [325]. 224 Ra emits abundant gamma emissions at 241 keV that can be employed for SPECT imaging [325].…”

Section: Production and Availabilitymentioning

confidence: 99%

Radiometals in Imaging and Therapy: Highlighting Two Decades of Research

Sharma,

Pandey

2023

Pharmaceuticals

View full text Add to dashboard Cite

The present article highlights the important progress made in the last two decades in the fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based positron emission tomography, single photon emission computerized tomography, and radionuclide therapy are illustrated in terms of their production routes and ease of radiolabeling. Applications in clinical diagnostic and radionuclide therapy are considered, including human studies under clinical trials; their current stages of clinical translations and findings are summarized. Because the metalloid astatine is used for imaging and radionuclide therapy, it is included in this review. In regard to radionuclide therapy, both beta-minus (β−) and alpha (α)-emitting radionuclides are discussed by highlighting their production routes, targeted radiopharmaceuticals, and current clinical translation stage.

show abstract

111In and 131I labeled nimotuzumabs for targeted radiotherapy of a murine model of glioma

Liao

Tang

Liu

et al. 2023

J Radioanal Nucl Chem

View full text Add to dashboard Cite

Simple and efficient method for producing high radionuclidic purity 111In using enriched 112Cd target

Cited by 6 publications

References 23 publications

In Vitro Anticancer Ability of Nano Fluorescent ¹¹¹In‐MIL‐68/PEG‐FA on Hela Cells

In Vitro Anticancer Ability of Nano Fluorescent ¹¹¹In‐MIL‐68/PEG‐FA on Hela Cells

Radiometals in Imaging and Therapy: Highlighting Two Decades of Research

111In and 131I labeled nimotuzumabs for targeted radiotherapy of a murine model of glioma

Contact Info

Product

Resources

About

Simple and efficient method for producing high radionuclidic purity 111In using enriched 112Cd target

Cited by 6 publications

References 23 publications

In Vitro Anticancer Ability of Nano Fluorescent 111In‐MIL‐68/PEG‐FA on Hela Cells

In Vitro Anticancer Ability of Nano Fluorescent 111In‐MIL‐68/PEG‐FA on Hela Cells

Radiometals in Imaging and Therapy: Highlighting Two Decades of Research

111In and 131I labeled nimotuzumabs for targeted radiotherapy of a murine model of glioma

Contact Info

Product

Resources

About

In Vitro Anticancer Ability of Nano Fluorescent ¹¹¹In‐MIL‐68/PEG‐FA on Hela Cells

In Vitro Anticancer Ability of Nano Fluorescent ¹¹¹In‐MIL‐68/PEG‐FA on Hela Cells